PERSONENI, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 1665
EU - Europa 258
AS - Asia 89
AF - Africa 71
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 2102
Nazione #
US - Stati Uniti d'America 1626
IT - Italia 90
NG - Nigeria 65
CA - Canada 38
FR - Francia 37
NL - Olanda 35
GB - Regno Unito 27
DE - Germania 21
CN - Cina 19
BE - Belgio 16
TR - Turchia 12
IN - India 11
HK - Hong Kong 9
SG - Singapore 9
JP - Giappone 8
CL - Cile 7
FI - Finlandia 7
EG - Egitto 6
IR - Iran 6
EU - Europa 5
IL - Israele 5
AT - Austria 4
RU - Federazione Russa 4
AU - Australia 3
BD - Bangladesh 3
CZ - Repubblica Ceca 3
KR - Corea 3
UA - Ucraina 3
A2 - ???statistics.table.value.countryCode.A2??? 2
ES - Italia 2
ID - Indonesia 2
NO - Norvegia 2
PL - Polonia 2
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
HU - Ungheria 1
MD - Moldavia 1
MM - Myanmar 1
MX - Messico 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
Totale 2102
Città #
Chandler 469
Wilmington 413
San Mateo 165
Ann Arbor 134
Lawrence 84
Princeton 84
Leawood 78
Benin City 65
Milan 38
Paris 36
Amsterdam 34
Woodbridge 31
Boardman 26
Fairfield 23
London 17
Toronto 17
Brussels 15
San Diego 14
Kocaeli 9
Abbiategrasso 8
Andover 7
Helsinki 7
Montreal 7
Norwalk 7
Seattle 7
Singapore 7
Monmouth Junction 6
Redwood City 6
Cairo 5
Redmond 5
Winnipeg 5
Falls Church 4
Los Angeles 4
Shanghai 4
Shenzhen 4
Tai Kok Tsui 4
Ashburn 3
Hanover 3
Raleigh 3
Sacramento 3
Verona 3
Ariano nel Polesine 2
Carrara 2
Clearwater 2
Dhaka 2
Jakarta 2
Lambeth 2
Minatomirai 2
Montréal 2
Moscow 2
Munich 2
Okayama 2
Phoenix 2
Prague 2
Rome 2
Sherbrooke 2
Warsaw 2
Ankara 1
Bengaluru 1
Brighton 1
Bucharest 1
Budapest 1
Caderzone 1
Cambridge 1
Central 1
Central District 1
Changchun 1
Chicago 1
Chisinau 1
Chittagong 1
Chula Vista 1
Concord 1
Copenhagen 1
Croydon 1
Daly City 1
Des Moines 1
Eden Prairie 1
Edogawa 1
Egham 1
Erzincan 1
Florence 1
Fort Lauderdale 1
Frankfurt am Main 1
Frederick 1
Gelsenkirchen 1
Guelph 1
Gurgaon 1
Hayward 1
Hebei 1
Henderson 1
Hyderabad 1
Incheon 1
Istanbul 1
Jilove u Prahy 1
Kemerovo 1
Laval 1
Lavis 1
Lexington 1
Lima 1
Manassas 1
Totale 1939
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 96
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 51
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 50
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 42
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 39
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 38
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 38
Cabozantinib for the treatment of hepatocellular carcinoma 36
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 36
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 36
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 36
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 36
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 35
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 34
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 33
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 33
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 32
Reply to Y. Pointreau et al 32
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 32
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 32
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 31
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 31
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 31
Role of liver biopsy in hepatocellular carcinoma 31
Biomarkers in Hepatocellular Carcinoma-Letter 30
COVID-19 and liver cancer clinical trials: not everything is lost 30
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 30
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 30
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 30
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 30
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 29
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 28
Shaping the landscape of immune oncology in hepatocellular carcinoma 28
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 28
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 28
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 27
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 27
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 27
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 26
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 26
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 26
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 26
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 26
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 26
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 26
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 26
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 26
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 25
Tivantinib for hepatocellular carcinoma 25
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 25
Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E-Mediated Anaphylaxis Reply 24
Regorafenib for the treatment of unresectable hepatocellular carcinoma 23
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 23
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 23
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 23
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 23
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 22
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 22
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 21
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 21
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 21
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 20
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 20
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 20
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 19
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 19
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 19
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 18
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 16
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 16
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 16
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 16
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 12
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 11
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 10
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 10
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 10
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 9
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 9
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 9
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 9
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 8
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 8
OncoAlert Round Table Discussions: The Global COVID-19 Experience. 7
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 7
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 5
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 5
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 5
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. 4
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 4
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 4
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 2
Totale 2225
Categoria #
all - tutte 10865
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10865


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0000 00 00 0036
2020/2021772 4564 23234 11947 136961088
2021/2022557 1582106 1614 2481 641058339
2022/2023887 19881138189 150120 110 0000
Totale 2225